Phase II Study of Cholesterol- and Cholestanol-Free Diet, Lovastatin, and Chenodeoxycholic Acid for Cerebrotendinous Xanthomatosis



Status:Recruiting
Conditions:Neurology
Therapuetic Areas:Neurology
Healthy:No
Age Range:Any
Updated:4/2/2016
Start Date:January 1996

Use our guide to learn which trials are right for you!

Effects of Diet and Medication in Patients With Cerebrotendinous Xanthomatosis (CTX)

OBJECTIVES: I. Assess the biosynthesis of cholesterol and cholestanol, and measure the
turnover of individual sterols and bile acids in patients with cerebrotendinous
xanthomatosis before and after a cholesterol- and cholestanol-free diet.

II. Assess the biosynthesis of cholesterol and cholestanol, and measure the turnover of
individual sterols and bile acids in these patients before and after lovastatin and
chenodeoxycholic acid.

PROTOCOL OUTLINE: Following a 2-week baseline assessment, patients participate in a feeding
study for up to 3 weeks. The diet is free of cholesterol and cholestanol.

For the next 4 weeks, patients return to their typical diet and are medicated with daily
lovastatin and chenodeoxycholic acid.

The feeding study is repeated for an additional 3 weeks, with the patient taking either
lovastatin or chenodeoxycholic acid.

PROTOCOL ENTRY CRITERIA: Cerebrotendinous xanthomatosis
We found this trial at
1
site
3181 Southwest Sam Jackson Park Road
Portland, Oregon 97239
503 494-8311
Oregon Health and Science University In 1887, the inaugural class of the University of Oregon...
?
mi
from
Portland, OR
Click here to add this to my saved trials